Skip to main content
. 2021 Jul 21;16:4913–4928. doi: 10.2147/IJN.S317113

Figure 3.

Figure 3

Ng(-)pIL-12 adjuvant induced robust HBV-specific CD8+ and CD4+ T cell responses during vaccination. C57 BL/6J mice were injected intramuscularly with three doses of PBS, 2 μg HBsAg alone, 2 μg HBsAg combined with 45 μg Ng(-)pIL-12 at two-week intervals, separately. (A) The proportion of CD11ahi CD8αlo cells among CD8+ T cells in the peripheral blood on day 7, 21 and 35 after the initiation of immunisation. (B) The proportion of CD11ahi CD49dhi cells among CD4+ T cells in the peripheral blood on day 7, 21 and 35 after the initiation of immunisation. (C) The expression of activation antigen CD69 on CD4+ CD11ahi CD49dhi cells on day 7 after the initiation of immunisation. HBsAg, HBsAg alone; Ng(-)pIL-12, 40 μg Ng(-) containing 5 μg pIL-12. All data are expressed as the mean ± SEM (n ≥ 5) from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.